surmount-1 trial tirzepatide weight loss non-diabetic π Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with obesity or overweight but without diabetes. Researchers Semaglutide vs. Tirzepatide for Obesity
Pay in 4 interest-free payments of $7.34 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 23 - Aug 28























